Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313704 | 0.82 | IGF1R (0.59) | PIK3CAIGF1R | |
| SCHEMBL6313126 | 0.79 | HTR3A (0.52) | PIK3CAIGF1RKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL6318862 | 0.77 | DHFR (0.56) | PIK3CAIGF1RKDM4E | |
| SCHEMBL881132 | 0.77 | PIK3CA (0.70) | PIK3CAIGF1R | |
| SCHEMBL6318945 | 0.76 | TNF (0.44) | PIK3CASMN1; SMN2 | |
| SCHEMBL10327901 | 0.76 | PIK3CA (0.68) | PIK3CA | |
| SCHEMBL6312244 | 0.75 | CYP1A2 (0.52) | PIK3CAKDM4ENPC1SMN1; SMN2HSD17B10 | |
| SCHEMBL6315288 | 0.75 | PDGFRB (0.49) | PIK3CAKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL10328050 | 0.75 | PIK3CA (0.71) | PIK3CA | |
| SCHEMBL10328079 | 0.74 | PIK3CA (0.66) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | claimed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | claimed |
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | PIK3CA 423/4885CNR2 1036/4885IGF1R 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.